Congenital and pediatric interstitial disease

Current Opinion in Pulmonary Medicine

Volumn 2, Issue 5, 1996, Pages 347-356

  Bush, Andrew ^a   Du Bois, Roland ^a  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

LUNG SURFACTANT;

ADULT; AGE; CHILD; GROWTH, DEVELOPMENT AND AGING; HISTIOCYTOSIS; HUMAN; IMMUNOLOGY; INTERSTITIAL LUNG DISEASE; LUNG; PATHOPHYSIOLOGY; PRESCHOOL CHILD; REVIEW; TREATMENT OUTCOME;

ADULT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; HISTIOCYTOSIS; HUMANS; LUNG; LUNG DISEASES, INTERSTITIAL; PULMONARY SURFACTANTS; TREATMENT OUTCOME;

EID: 0030225390     PISSN: 10705287     EISSN: None     Source Type: Journal    
DOI: 10.1097/00063198-199609000-00002     Document Type: Article

References (119)

1. Bokulic RE, Hilmann BC: Interstitial lung disease in children. Pediatr Clin North Am 1994, 41:543-567.
2. Fan LL, Langston C: Chronic interstitial lung disease in children. Pediatr Pulmonol 1993, 16:184-196.
3. Fan LL, Mullen AL, Brugman SM, Inscore SC, Parks DP, White CW: Clinical spectrum of chronic interstitial lung disease in children. J Pediatr 1992, 124:867-872.
4. Sondheimer HM, Lung MC, Brugman SM, Ikle DN, Fan LL, White CW: Pulmonary vascular disorders masquerading as interstitial lung disease. Pediatr Pulmonol 1995, 20:284-288. Eight of 92 children appraised for ILD who were shown to have a variety of vascular disorders are reviewed. Not all that looks interstitial on the chest radiograph turns out to have ILD!
5. Reid L: Lung growth in health and disease. Br J Dis Chest 1984, 74:113-139.
6. McGowan SE: Extracellular matrix and the regulation of lung development and repair. FASEB J 1992, 6:2695-2904.
7. Minoo P, King RJ: Epithelial-mesenchymal interactions in lung development. Annu Rev Physiol 1994, 56:13-45.
8. Hislop A, Wigglesworth JS, Desai R: Alveolar development in the human fetus and infant. Early Hum Dev 1986, 13:1-11.
9. Thurlbeck WM: Postnatal human lung growth. Thorax 1982, 37:564-571.
10. Dunnill MS: The problem of lung growth. Thorax 1982, 37:561-563.
11. Thibeault DW, Heimes B, Rezaiekhaligh M, Mabry S: Chronic modifications of lung and heart development in glucocorticoid-treated newborn rats exposed to hyperoxia or room air. Pediatr Pulmonol 1993, 16:81-88.
12. Chan KN, Noble-Jamieson CM, Elliman A, Bryan EM, Silverman M: Lung function in children of low birthweight. Arch Dis Child 1989, 64:1284-1293.
13. Holt PG, Willet K: Host defenses and Immunology. In Childhood Asthma and Other Wheezing Disorders. Edited by Siverman M. London: Chapman and Hall; 1995:67-86. A beautiful review of the maturational changes of all arms of the immune system; an essential read for all pediatric pulmonologists. The immune system of the infant is radically different from that of the adult, and this has important implications for the pathogenesis of ILD.
14. Pirenne H, Aujard Y, Eljaafari A, Bourillon A, Oury JF, Le Gac S, et al.: Comparison of T cell functional changes during childhood with the ontogeny of CDw29 and CD45RA expression on CD4+ T cells. Pediatr Res 1992, 32:81-86.
15. Stern DA, Hicks MJ, Martinez FD, Holberg CJ, Wright AL, Pinnas J, et al.: Lymphocyte subpopulation number and function in infancy. Dev Immunol 1992, 2:175-179.
16. Bertotto A, Gerli R, Lanfrancone L, Crupi S, Arcangeli C, Cerne HC, et al.: Activation of cord T lymphocytes. II. Cellular and molecular analysis of the defective response induced by anti-CD3 monoclonal antibody. Cell Immunol 1990, 127:247-259.
17. Gerli R, Agea E, Muscat C, Tognelli R, Fiorucci G, Spinozzi F, et al.: Activation of cord T lymphocytes. III. Role of LFA-1/ICAM-1 and CD2/LFA-3 adhesion molecules in CD3-induced proliferative response. Cell Immunol 1993, 148:32-47.
18. Gerli R, Bertotto A, Crupi S, Arcangeli C, Marinelli I, Spinozzi F, et al.: Activation of cord T lymphocytes. I. Evidence for a defective T cell mitogenesis induced through the CD2 molecule. J Immunol 1993, 142:2583-2589.
19. Lawler SD, Ukaejiojo EO, Reeves BR: Interaction of maternal and neonatal cells in mixed-lymphocyte cultures. Lancet 1975, 2:1185-1187.
20. Olding LB, Oldstone MB: Thymus derived peripheral lymphocytes from human newborns inhibit division of their mother's lymphocytes. J Immunol 1976, 116:682-686.
21. Miyawaki TH, Seki H, Taga K, Sato H, Taniguchi N: Dissociated production of interleukln-2 and immune gamma interferon by phytohaemagglutinen stimulated lymphocytes in healthy infants. Clin Exp Immunol 1985, 59:505-511.
22. Watson W, Oen K, Ramdahin R, Harman C: Immunoglobulin and cytokine production by neonatal lymphocytes. Clin Exp Immunol 1991, 83:169-174.
23. Lewis DB, Yu CC, Meyers J, English BK, Kahn SJ, Wilson CB: Cellular and molecular mechanisms for reduced interleukin 4 and interferon-gamma production by neonatal T cells. J Clin Invest 1991, 87:194-202.
24. Conley ME, Cooper MD: Immature IgA B cells in IgA-deficient patients. N Engl J Med 1981, 317:495-501.
25. Cooper MD: Current concepts. B lymphocytes, normal development and function. N Engl J Med 1987, 317:1452-1459.
26. Gathings WE, Kubagawa H, Cooper MD: A distinctive pattern of B cell immaturity in perinatal humans. Immunol Rev 1981, 57:107-114.
27. Splawski JB, Jelinek DF, Lipsky PE: Delineation of the functional capacity of human neonatal lymphocytes. J Clin Invest 1991, 87:545-553.
28. D'Ambola JB, Sherman MP, Taskin DP, Gong H: Human and rabbit newborn lung macrophages have reduced anti-candida activity. Pediatr Res 1988, 24:285-290.
29. + accessory cells in fetal and newborn rat lung. Am J Respir Cell Mol Biol 1992, 6:349-356.
30. Hill HR: Biochemical, structural, and functional abnormalities of polymorphonuclear leucokytes in the neonate. Pediatr Res 1987, 22:375-382.
31. Fink JN: Hypersensitivity pneumonitis. Clin Chest Med 1992, 13:303-9.
32. Epler GR, McCleod TC, Gaensler EA, Mikus JP, Carrington CB: Normal chest roentgenograms in diffuse infiltrative lung disease. N Engl J Med 1978, 298:934-939.
33. Stam H, Beek Avd, Grunberg K, Stijnen T, Tiddens HA, Versprille A: Pulmonary diffusing capacity at reduced alveolar volumes in children. Pediatr Pulmonol 1996, 21:84-89. Important description of errors involved in interpreting carbon monoxide transfer without reference to lung volumes. Includes reference equations with which to make appropriate corrections.
34. Clement C, Chadelet K, Masliah J, Mousset B, Sardet A, Grimfeld A, Tournier G: A controlled study of oxygen metabolite release by alveolar macrophages in children with interstitial lung disease. Am Rev Respir Dis 1987, 136:1424-1428.
35. Riedler J, Grigg J, Stone C, Tauro G, Robertson CF: Bronchoalveolar lavage cellularity in healthy children. Am J Respir Crit Care Med 1995, 152:163-168. An important paper that attempts to standardize the muddy waters of pediatric BAL.
36. Auerswald U, Barth J, Magnussen H: Value of CD-1-positive cells in bronchoalveolar lavage fluid for the diagnosis of pulmonary histiocytosis X. Lung 1991, 169:305-309.
37. Zaki M, Al Saleh Q, Al Mutari G: Effectiveness of chloroquine therapy in idiopathic pulmonary hemosiderosis. Pediatr Pulmonol 1995, 20:125-6. Only a case report, but the condition is so rare that it is worth considering. Another report confirming the apparently successful use of chloroquine in idiopathic pulmonary hemosiderosis.
38. Orens JB, Kazerooni EA, Martinez FJ, Curtis JL, Gross BH, Flint A, Lynch JP: The sensitivity of high-resolution CT in detecting idiopathic pulmonary fibrosis proved by open lung biopsy. Chest 1995, 108:109-115.
39. Lynch DA, Newell JD, Logan PM, King TE, Muller NL: Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? AJR Am J Roentgenol 1995, 165:807-811.
40. Mullins D, Livne M, Mallory GB, Kemp JS: A new technique for transbronchial biopsy in infants and small children. Pediatr Pulmonol 1995, 20:253-257. An important adaptation of neonatal fiberoptic bronchoscopy. A suction catheter is positioned using the bronchoscope, and biopsies are taken down the suction tube after the bronchoscope has been removed.
41. Mackenzie AH: Pharmacological actions of 4-aminoquinolone compounds. Am J Med 1983, 75 (suppl):5-10.
42. Szilagyi T, Kavai M: The effect of chloroquine on the antigen-antibody reaction. Acta Physiol Hung 1970, 38:411-417.
43. Salmeron G, Lipsky PE: Immunosuppressive potential of antimalarials. Am J Med 1983, 75:19-24.
44. Sharie N, Crawford OF, Dinwiddie R: Fibrosing alveolitis and desquamative interstitial pneumonitis. Pediatr Pulmonol 1994, 17:359-365.
45. Avital A, Godfrey S, Maayan Ch, Diamant Y, Springer C: Chloroquine treatment of interstitial lung disease in children. Pediatr Pulmonol 1994, 18:356-360.
46. Katzenstein A-L, Gordon LP, Oliphant M, Swender PT: Chronic pneumonitis of infancy. Am J Surg Pathol 1995, 19:439-447. A description of nine infants forming part of the spectrum of neonatal lung disease; it concentrates on the pathological features. The numbers were too few for the results to be certain, but there was an apparent response to chloroquine.
47. Blanco A, Sous P, Gomez S, Valbuena C, Telleria JJ: Antineutrophil cytoplasmic antibodies (ANCA) in idiopathic pulmonary hemosiderosis. Pediatr Allergy Immunol 1994, 5:235-239.
48. Bush A, Shepherd MN, Warner JO: Chloroquine in idiopathic pulmonary haemosiderosis. Arch Dis Child 1992, 67:625-627.
49. Leahy F, Pasterkamp H, Tal A: Desquamative interstitial pneumonia responsive to chloroquine. Clin Pediatr 1985, 24:230-232.
50. Rynes RI: Ophthalmologic safety of long-term hydroxychloroquine sulfate treatment. Am J Med 1983, 75:35-39.
51. Rynes RI, Bernstein HN: Ophthalmologic safety profile of antimalarial drugs. Lupus 1993, 2 (suppl 1):S17-S19.
52. Fauroux B, Meyer-Milsztain A, Boccon-Gibod L, Leverger G, Clement A, Biour M, Tournier G. Cytotoxic drug-induced pulmonary disease in infants and children. Pediatr Pulmonol 1994, 18:347-355.
53. Nysom K, Holm K, Hesse B, Ulrik CS, Jacobsen N, Bisgaard H, Hertz H: Lung function after allogeneic bone marrow transplantation for leukaemia or lymphoma. Arch Dis Child 1996, 74:432-436. Long-term and very complete follow-up of a cohort of survivors of bone marrow transplantation. A pointer to the need for very long-term follow-up in this group of children.
54. Hartsell WF, Czyzewski EA, Ghalie R, Kaizer H: Pulmonary complications of bone marrow transplantation: a comparison of total body irradiation and cyclophosphamide to busulfan and cyclophosphamide. Int J Radiat Oncol Biol Phys 1995, 32:69-73.
55. Carlson K, Backlund L, Smedmyr B, Oberg G, Simonsson B: Pulmonary function and complications subsequent to autologous bone marrow transplantation. Bone Marrow Transplant 1994, 14:805-811.
56. Girinsky T, Socie G, Ammarguekkat H, Cosset JM, Briot E, Bridier A, Gluckman E: Consequences of two different doses to lungs during a single dose of total body irradiation: results of a randomised study on 85 patients. Int J Radiat Oncol Biol Phys 1994, 30:821-824.
57. Jakacki RI, Schramm CM, Donahue BR, Haas F, Allen JC: Restrictive lung disease following treatment for malignant brain tumors: a potential late effect of craniosplnal irradiation. J Clin Oncol 1995, 13:1478-1485.
58. O'Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattamaheni HR, Woodcock AA: Active lung fibrosis up to 17 years after chemotherapy with carmustine (B.C.N.U.) in childhood. N Engl J Med 1990, 323:378-382.
59. O'Driscoll BR, Kalra S, Gattamaneni HR, Woodcock AA: Late carmustine lung fibrosis. Age at treatment may influence severity and survival. Chest 1995, 107:1355-1357. Very important follow-up paper that extends previous observations and confirms the sinster reputation of nitrosoureas, especially in those younger than 6 years of age at time of treatment.
60. Marina NM, Greenwald CA, Fairclough DL, Thompson EI, Wilimas JA, Mackert PW, et al.: Serial pulmonary function studies in children treated for newly diagnosed Hodgkin's disease with mantle radiotherapy plus cycles of cyclophosphamide, vincristine, and procarbazine alternating with cycles of bleomycin, vinblastine, and dacarbazine. Cancer 1995, 75:1706-1711. Do not be put off by the unwieldy title. An excellent account of the use of carbon monoxide transfer to monitor cytotoxic dosage.
61. Lund MB, Kongerud J, Nome O, Abrahamsen AF, Bjortuft O, Forfang K, Boe J: Lung function impairment in longterm survivors of Hodgkin's disease. Ann Oncol 1995, 6:495-501.
62. MacNaughten PD, Morgan CJ, Denison DM, Evans TW: Pulmonary function testing in the intensive care unit. Respir Med 1990, 84:437-443.
63. Egeler RM, D'Angio GJ: Langerhans cell histiocytosis. J Pediatr 1995, 127:1-11. Excellent, up-to-date review of all aspects of Langerhans cell histiocytes.
64. Casaro MA, Bernaudin JF, Saltini C, Ferrans VJ, Crystal RG: Accumulation of Langerhans cells on the epithelial surface of the lower respiratory tract in normal subjects in association with cigarette smoking. Am Rev Respir Dis 1968, 137:406-411.
65. Kelly KM, Beverley PC, Chu AC, Davenport V, Gordon I, Smith M, Pritchard J: Succesful in vivo immunolocalization of Langerhans cell histiocytosis with use of a monoclonal antibody, NA1/34. J Pediatr 1994, 125:717-722.
66. Kelly KM, Pritchard J: Monoclonal antibody therapy in Langerhans cell hlstiocytosis-feasible and reasonable? Br J Cancer 1994, 70 (SXXIII):S54-S55.
67. Writing group of the Histiocyte Society: Histiocytic syndromes in children. Lancet 1987, 1:208-209.
68. Ben-Ezra JM, Koo CH: Langerhans cell histiocytosis and malignancies of the M-PIRE system. Am J Clin Pathol 1993, 99:464-471.
69. Emile J-F, Wechsler J, Brousse N, Boulland ML, Cologon R, Fraitag S, et al.: Langerhans' cell histiocytosis: definitive diagnosis with the use of monoclonal antibody O10 on routinely paraffin-embedded samples. Am J Surg Pathol 1995, 19:636-641. Describes important histologic techniques, particularly those for retrospective review of difficult diagnoses.
70. Walsh LJ, Seymour GJ, Powell RN: The regulation of Langerhans cell T6, DR, and DQ antigen expression: an hypothesis. J Oral Pathol 1988, 17:43-46.
71. Ishii T, Walsh LJ, Seymour GJ, Powell RN: Modulation of Langerhans cell surface antigen expression by recombinant cytokines. J Oral Pathol Med 1990, 19:355-359.
72. Emile J-F, Fraitag S, Leborgne M, de Prost Y, Brousse N: Langerhans cell histiocytosis cells are activated Langerhans' cells. J Pathol 1994, 174:71-76.
73. Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, Gilliland DG: Langerhans' cell histiocytosis (histiocytosis X): a clonal proliferative disease. N Engl J Med 1994, 331:154-160.
74. Yu RC, Chu C, Buluwela L, Chu AC: Clonal proliferation of Langerhans cells in Langerhans cell histiocytosis. Lancet 1994, 343:767-768.
75. Weiss LM, Wood GS, Trela M: Clonal T cell populations in lymphomatoid papulosis: evidence of a lymphoproliferative origin for a clinically benign disease. N Engl J Med 1986, 315:475-479.
76. McCain K, Jin H, Gresik V, Favara B: Langerhans cell histiocytosis: lack of a viral etiology. Am J Hematol 1994, 47:16-20.
77. Mierau GW, Wills EJ, Steele PO: Ultrastructural studies in Langerhans cell histiocytosis: a search for evidence of a viral etiology. Pediatr Pathol 1994, 14:895-904.
78. McLelland J, Broadbent V, Yeomans E, Malone M, Pritchard J: Langerhans cell histiocytosis: the case for conservative treatment. Arch Dis Child 1990, 65:301-303.
79. Egeler RM, Nesbit ME: Langerhans cell histiocytosis and other disorders of monocyte-histiocyte lineage. Crit Rev Oncol Hematol 1995, 18:9-35.
80. Arico M, Colella R, Conter V, Indolfi P, Pession A, Santoror N, Burgio GR: Cyclosporine therapy for refractory Langerhans cell histiocytosis. Med Pediatr Oncol 1995, 25:12-16. A small, open study of cyclosporine in Langerhans cell histiocytosis, with promising results. Should be read by anyone caring for a child who is doing poorly with conservative treatment.
81. Tzortzatou-Stathopoulou F, Xaidara A, Mikraki V, Moschovi M, Arvanitis D, Ageloyianni P, Prodromou P: Effect of trimethoprim-sulphamethoxazole in Langerhans' cell histiocytosis: preliminary observations. Med Pediatr Oncol 1995, 25:74-78. Open study, done over 4 years, of a relatively harmless treatment for Langerhans cell histiocytosis. Poor response seen in patients with lung disease, but nonetheless an interesting approach.
82. Popper HH, Zenz W, Mache C, Ohlinger W: Familial haemophagocytic lymphohistiocytosis. A report of three cases with unusual lung involvement. Histopathology 1994, 25:439-445.
83. Schwebke K, Henry K, Balfour HH, Olson D, Crane RT, Jordan MC: Congenital cytomegalovirus infection as a result of nonprimary cytomegalovirus disease in a mother with acquired immunodeficiency syndrome. J Pediatr 1995, 126:293-295.
84. Chetcuti PAJ, Ball RJ: Surfactant apoprotein B deficiency. Arch Dis Child 1995, 73:F125-F127. A detailed annotation that describes the background to recent developments and provides an excellent introduction to the subject.
85. McDonald JW, Roggli VL, Bradford WB: Coexisting endogenous and exogenous lipoid pneumonia and pulmonary alveolar proteinosis in a patient with neurodevelopmental disease. Pediatric Pathol 1994, 14:505-511.
86. Hamm H, Kroegel C, Hohlfeld J: Surfactant: a review of its functions and relevance in adult respiratory disorders. Respir Med 1996, 90:251-270. A good review of all aspects of surfactant physiology and metabolism, recommended as an introduction to the subject.
87. Weaver T, Whitsett J: Function and regulation of pulmonary surfactant associated proteins. Biochem J 1991, 273:249-264.
88. Possmeyer F: Pulmonary perspective: a proposed nomenclature for pulmonary surfactant associated proteins. Am Rev Respir Dis 1988, 138:990-998.
89. Van Golde L: Potential role of surfactant proteins A and D in innate defence against pathogens. Biol Neonate 1995, 67 (suppl 1):2-17.
90. Suzuki Y, Futija Y, Kogishi I: Reconstitution of tubular myelin from synthetic lipids and proteins associated with pig pulmonary surfactant. Am Rev Respir Dis 1989, 140:75-81.
91. Chung JS, Yu SH, Whitsett JA, Harding PCR, Possmayer F: Effect of surfactant-associated protein-A (SP-A) on the activity of lipid extract surfactant. Biochem Biophys Acta 1989, 1002:348-358.
92. Kuroki Y, Mason RJ, Voelker DR: Pulmonary apoprotein A structure and modulation of surfactant secretion by rat alveolar type 11 cells. J Biol Chem 1988, 263:3388-3394.
93. van Iwaarden, Welmers FB, Verhoef J, Haagsman HP, van Golde LM: Pulmonary surfactant protein A enhances the host-defence mechanism of rat alveolar macrophages. Am J Respir Cell Mol Biol 1990, 2:91-98.
94. Whitsett JA, Nogee LM, Weaver TE, Horowitz AD: Human surfactant protein B: structure, function, regulation, and genetic disease. Physiol Rev 1995, 75:749-757. Detailed review of the basic science of SP-B and the consequences of SP-B deficiency.
95. Kuan SF, Rust K, Crouch E: Interactions of surfactant protein D with bacterial lipopolysaccharides: surfactant protein D is an Escherischia coli-binding protein in bronchoalveolar lavage. J Clin Invest 1992, 90:97-106.
96. Kuan SF, Persson A, Parghi D, Crouch E: Lectin mediated interactions of surfactant protein D with alveolar macrophages. Am J Respir Cell Mol Biol 1994, 10:430-436.
97. van Iwaarden, Shimizu H, van Golde PH, Voelker DR, van Golde LM: Rat surfactant protein D enhances the production of oxygen radicals by rat alveolar macrophages. Biochem J 1992, 286:5-8.
98. Voorhout W, Veenendaal T, Haagsman H, Weaver T, Whitsett J, Van Golde L, et al.: Intracellular processing of pulmonary surfactant protein B in an endosomal/lysosomal compartment. Am J Physiol 1992, 263:L479-L486.
99. Hawgood S, Latham D, Borchelt J, Damm D, White T, Benson B, et al.: Cell specific post-translational processing of the surfactant associated protein SP-B. Am J Physiol 1993, 264:L290-L299.
100. Robertson B, Kobayashi T, Ganzuka M, Grossman G, Li W, Suzuki Y: Experimental neonatal respiratory failure induced by monoclonal antibody to the hydrophobia surfactant associated protein SP-B. Pediatr Res 1991, 30:239-243.
101. Kobayashi T, Robertson B, Grossman G, et al.: Exogenous porcine surfactant (Curosurf) is inactivated by monoclonal antibody to the surfactant-associated hydrophobic protein SP-B. Acta Paediatr 1992, 81:665-671.
102. Suzuki Y, Robertson B, Fujita Y, Grossman G, Kogishi K, Curstedt T: Lung protein leakage in respiratory failure induced by a hybridoma making monoclonal antibody to the hydrophobic surfactant-associated polypeptide SP-B. Int J Exp Pathol 1992, 73:325-333.
103. Herman T, Nogee L, McAlister W, Dehner L: Surfactant protein B deficiency: radiographic manifestations. Pediatr Radiol 1993, 23:373-375.
104. deMello D, Nogee L, Heyman S, Krous H, Hussain M, Merritt T, et al.: Molecular and phenotypic variability in the congenital alveolar proteinosis syndrome associated with inherited surfactant protein B deficiency. J Pediatr 1994, 124:43-50.
105. Schagger H, von Jagour G: Tricine-sodium dodectyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1-100 kDa. Ann Biochem 1987, 166:368-379.
106. Pryhuber G, Hull W, Fink I: Ontogeny of surfactant proteins A & B in human amniotic fluid as indices of foetal lung maturity. Pediatr Res 1991, 50:597-605.
107. deMello D, Phelps D, Patel G: Expression of 35 kDa and low molecular weight surfactant-associated proteins in the lungs of infants dying with respiratory distress syndrome. Am J Pathol 1989, 134:1285-1293.
108. deMello D, Heyman S, Phelps D, Hamvas A, Nogee L, Cole S, Colten HR: Ultrastructure of lung in surfactant protein B deficiency. Am J Respir Cell Mol Biol 1994, 11:230-239.
109. Vorbroker DK, Profitt SA, Nogee LM, Whitsett JA: Aberrant processing of surfactant protein C in hereditary SP-B deficiency. Am J Physiol 1995, 268:L647-L656. Detailed molecular biology analysis of abnormalities in SP-C associated with congenital SP-B deficiency, including speculation as to the contribution of SP-C to the clinical picture.
110. Nogee L, Garnier G, Singer L, Dietz H, Murphy A, Cutting G, et al.: A mutation in the surfactant protein B gene responsible for fatal neonatl respiratory disease in multiple kindreds. J Clin Invest 1994, 93:1860-1863.
111. Hamvas A, Nogee L, deMello D, Cole F: Pathophysiology and treatment of surfactant protein B deficiency. Biol Neonate 1995, 67 (Suppl 1):18-31.
112. Wert SE, Profitt SA, Vorbroker DK, Hull WM, Nogee LM, Whitestt JA: Immunohistochemical analysis of surfactant protein B (SP-B) deficiency in patients with heterogeneic SP-B mutations. Pediatr Res 1995, 37:356A.
113. Ballard PL, Nogee LM, Beers MF, Ballard RA, Planer BC, Polk L, et al.: Partial deficiency of surfactant protein B in an infant with chronic lung disease. Pediatrics 1995, 96:1046-1052. An important case report of a new SP-B mutation; includes an excellent summary of present knowledge of the disease and its genetics.
114. Hamvas A, Nogee LM, deMello DE, Cole FS: Pathophysiology and treatment of surfactant protein-B deficiency. Biol Neonate 1995, 67 (Suppl 1):18-31.
115. Hamvas A, Cole FS, deMello DE, Moxley M, Whitsett JA, Colten HR, Nogee LM: Surfactant protein B deficiency: antenatal diagnosis and prospective treatment with surfactant replacement. J Pediatr 1994, 125:356-361.
116. Liley HG, White RT, Warr RG, Benson BJ, Hawgood S, Ballard PC: Regulation of messenger RNAs for the hydrophobic surfactant proteins in the human lung. J Clin Invest 1989, 83:1191-1197.
117. Yei S, Bachurski CJ, Weaver TE, Wert SE, Trapnell BC, Whitsett JA: Adenoviral-mediated gene transfer of human surfactant protein B to respiratory epithelial cells. Am J Respir Cell Mol Biol 1994, 11:329-336.
118. Dranoff G, Mulligan RC: Activities of granulocyte-macrophage colony stimulating factor revealed by gene transfer and gene knockout studies. Stem Cells (Dayt) 1994, 12 (suppl 1):173-184.
119. Sastry K, Ezekowitz R: Collectins: pattern recognition molecules involved in first line host defense. Curr Opin Immunol 1993, 5:59-66.